F S&P 500
5,209.75 -3.00 (-0.06%) F Dow Jones
39,182.00 -13.00 (-0.03%) F Nasdaq
18,164.75 -21.75 (-0.12%) E-mini Russell 2000 Index Futur
2,061.90 -2.90 (-0.14%) Petróleo
79.31 +0.32 (+0.41%) Oro
2,316.60 -5.70 (-0.25%)
Connect Biopharma Holdings Limited (CNTB)
Fuera de horario:
Connect Biopharma Holdings Limited
12265 El Camino Real
Suite 350
San Diego, CA 92130
United States
858 727 1040
https://www.connectbiopharm.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 81
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Wubin Pan M.B.A., Ph.D. | Co-Founder, President & Chairman of the Board of Directors | N/D | N/D | 1965 |
| Dr. Zheng Wei Ph.D. | Co-Founder, CEO & Director | N/D | N/D | 1964 |
| Mr. Steven Chan | Chief Financial Officer | N/D | N/D | 1972 |
| Mr. Jiang Bian J.D. | General Counsel & Chief Compliance Officer | N/D | N/D | N/D |
| Dr. Lei Sun Ph.D. | VP of Biologics & Head of CMC | N/D | N/D | 1964 |
| Dr. Raul Collazo Ph.D. | VP & Global Head of Medical Affairs | N/D | N/D | N/D |
| Dr. Malinda V. Longphre Ph.D. | VP & Head of US Clinical Operations | N/D | N/D | N/D |
Descripción
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.
Gestión corporativa
La calificación ISS Governance QuickScore de Connect Biopharma Holdings Limited a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
